Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May;31(5):1300-1310.
doi: 10.1002/oby.23744.

A randomized-controlled trial to evaluate the app-based multimodal weight loss program zanadio for patients with obesity

Lena Roth  1   2   3 , Madeleine Ordnung  4 , Katarina Forkmann  3 , Nora Mehl  3 , Annette Horstmann  1   2   4
Affiliations
Randomized Controlled Trial

A randomized-controlled trial to evaluate the app-based multimodal weight loss program zanadio for patients with obesity

Lena Roth et al. Obesity (Silver Spring). 2023 May.

Abstract

Objective: This study aimed to evaluate the effectiveness of the app-based, multimodal weight loss program zanadio.

Methods: A randomized-controlled trial was conducted from January 2021 to March 2022. A total of 150 adults with obesity were randomized into an intervention group and used zanadio for 1 year or into a wait list control group. The primary end point, weight change, and the secondary end points, quality of life, well-being, and waist to height ratio, were assessed every 3 months for up to 1 year via telephone interviews and online questionnaires.

Results: After 12 months, participants of the intervention group lost, on average, -7.75% (95% CI: -9.66% to -5.84%) of their initial weight, achieving a clinically relevant and statistically stronger weight reduction than the control group (mean = 0.00% [95% CI: -1.98% to 1.99%]). All secondary end points improved significantly in the intervention group, with significantly greater improvements in well-being and waist to height ratio than in the control group.

Conclusions: This study showed that adults with obesity who have used zanadio achieved a significant and clinically relevant weight loss within 12 months and improved further obesity-related health variables compared with a control group. Because of its effectiveness and flexible applicability, the app-based multimodal treatment zanadio might alleviate the present care gap for patients with obesity in Germany.

PubMed Disclaimer

References

REFERENCES

    1. World Health Organization. WHO European Regional Obesity Report 2022. WHO; 2022.
    1. Clark JM, Brancati FL. The challenge of obesity‐related chronic diseases. J Gen Intern Med. 2000;15(11):828‐829.
    1. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta‐analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220‐229.
    1. Must A, McKeown NM. The disease burden associated with overweight and obesity. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. MDText.com, Inc.; 2000.
    1. Kushner RF, Foster GD. Obesity and quality of life. Nutrition. 2000;16(10):947‐952.

Publication types